01 10Singulair
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 462
2019 Revenue in Millions : 698
Growth (%) : -34
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 413
2020 Revenue in Millions : 462
Growth (%) : -11
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 411
2021 Revenue in Millions : 413
Growth (%) : 0
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 404
2022 Revenue in Millions : 411
Growth (%) : -2
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2015 Revenue in Millions : 1,092
2014 Revenue in Millions : 931
Growth (%) : -15%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2014 Revenue in Millions : -8.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 915
2015 Revenue in Millions : 931
Growth (%) : -2
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 732
2016 Revenue in Millions : 915
Growth (%) : -20
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 708
2017 Revenue in Millions : 732
Growth (%) : -3%
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 698
2018 Revenue in Millions : 708
Growth (%) : -1
LOOKING FOR A SUPPLIER?